– Data from pivotal Phase III STARS study in short bowel syndrome with intestinal failure accepted as late-breaker oral presentation on May 21 at 10:30 am ET –
– Findings from the STARS.
01.05.2024 - Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, announced today that the company will present new data from studies evaluating apraglutide in adults with short bowel syndrome with intestinal failure (SBS-IF), a . Seite 1
Dublin, April 05, 2024 (GLOBE NEWSWIRE) The "Short Bowel Syndrome Market Insight, Epidemiology and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. Market Growth Trajectory Projected Outcomes A recent comprehensive analytical study has forecasted a substantial growth trajectory for the Short Bowel Syndrome (SBS) market in the 7 major markets (7MM), which include the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The to
USA: Findings from phase 3 STARS trial demonstrate the potential for apraglutide to improve the standard of care for all adult patients with short bowel syndrome with intestinal failure (SBS-IF).
Positive phase III data from Ironwood Pharmaceuticals Inc. with once-weekly glucagon-like peptide-2 analogue apraglutide failed to impress Wall Street, and shares of the Boston-based firm (NASDAQ:IRWD) closed Feb. 29 at $9.43, down $5.69, or 37.6%. The experiment called Stars tested apraglutide to reduce parenteral support in adults with short bowel syndrome with intestinal failure. Rare and severe, the condition affects about 18,000 adults in the U.S., Europe and Japan. Based on the latest data, Ironwood plans to submit an NDA to the U.S. FDA and other regulatory filings.